On March 23, 2026 Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, reported that its subsidiary Sapu Nano will present new data on everolimus toxicology, focusing on tissue concentration-driven effects, at the upcoming Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo, taking place March 22-25, 2026, in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will be featured during the Poster Session: ADME/Toxicokinetics I:
Date: Monday, March 23, 2026
Time (Author Attended): 1:45 PM – 4:15 PM
Display Time: 9:00 AM – 4:30 PM
Location: Exhibit Hall B, San Diego Convention Center
Abstract #: 3539
Poster Board #: K692
Presentation Title:
"Everolimus Toxicology: Tissue Concentration Effects"
Authors:
W. Chang, N. Chang, T. Hoque, and C. Lee
Sapu Nano, San Diego, CA
This poster presents new findings that elucidate the relationship between tissue-level exposure of everolimus and organ-specific toxicological outcomes, advancing understanding beyond traditional plasma pharmacokinetics.
"These data underscore the importance of tissue pharmacokinetics in determining toxicity profiles for mTOR inhibitors such as everolimus," said Wen-Han Chang PhD, Sr. Manager Nanomedicine. "Our findings provide a foundation for developing improved delivery strategies, including intravenous and nanoparticle-based formulations that better control biodistribution."
The SOT Annual Meeting and ToxExpo is the leading international forum for toxicology, bringing together scientists from academia, industry, and regulatory agencies to present cutting-edge research in safety science and drug development.
Sapu Nano’s participation highlights its continued leadership in nanomedicine and advanced drug delivery, with a focus on enhancing therapeutic index through precise control of drug distribution at the tissue level.
For more information about the meeting, visit:
www.toxicology.org/2026 | #2026SOT | #ToxExpo
(Press release, Oncotelic, MAR 23, 2026, View Source [SID1234663837])